

## RECTIVED

APR 0 1 2003

TECH CENTER 1600/2900

Attorney Docket No.<u>172.2USDC2</u> *PATENT* 

	IN THE UNITED STATE	ES PATENT	AND TRADEMARK	OFFICE
In re applica	ation of: Bischofberger et al			
Serial No.:	09/801,164	Group No.:	1653	***
Filed:	March 7, 2001	Examiner:	D. Lukton	Co
For:	Nucleotide Analogs			
_	Commissioner for Patents n, D.C. 20231			
	INFORMATION DISC	CLOSURE	STATEMENT (n	nodified)
List of Sect	ions Forming Part of This I	Information	Disclosure Stateme	nt.
The following	g sections are being submitte	ed for this In	formation Disclosure S	Statement:
1. X	Preliminary Statements			
2. X	FORM PTO - 1449 (Modified	)		
3. x	Identification of Prior Applicat	tion in Which	Listed Information W	as Already Cited.
<del></del>		<del></del>		
	CERT	IFICATE OF	MAILING	
attached or er	ify that this Information Disclonclosed) is being deposited on taddressed to the Assistant Comm	the date shov	n below with the United	States Postal Service in
	7 CFR 1.8 (a) ent postage as nail	<u>or</u>		37 CFR 1.10 ss Mail Post ddressee" Mailing
			Robin To	
Date:	rember 7, 2001		Solvin I	BUUS

(Signature of person mailing paper)





ection 1. Preliminary statements  $^{r_{EC_{H}}}_{CE_{N}}_{TE_{R}}_{1600/290}$  Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Identification of Prior Application in Which Listed Information Was Already Section 3. Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No.	09/247,497	, filed on	February 10, 1999
Serial No.	09/071,420	, filed on	May 1, 1998
Serial No.	08/617,849	, filed on	May 6, 1996
Serial No.	08/193,341	, filed on	February 8, 1994
Serial No.	08/123,483	, filed on	September 17, 1993

the references has any bearing under United States Law.

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043

Tel. No.: (650) 522-5878

Max D. Hensley

Type or print name of attorney Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404